Results 131 to 140 of about 7,229 (203)

Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study. [PDF]

Open Forum Infect Dis
Rosas Cancio-Suárez M, Moreno A, Terrón SDC, Vivancos MJ, Vélez Díaz-Pallarés M, Casado JL, Cano C, Navarro-Soler R, Moreno S, Pérez-Elías MJ.   +9 more
europepmc   +1 more source

Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible. [PDF]

Infez Med
Cossu MV, D'Avolio A, Ridolfo AL, Moschese D, Gori A, Cattaneo D, Gervasoni C.   +6 more
europepmc   +1 more source

Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort. [PDF]

Open Forum Infect Dis
Rial-Crestelo D, Llenas-García J, Hidalgo-Tenorio C, Troya García J, Galindo Puerto MJ, Alemán Valls MR, Torralba González de Suso M, Buzón L, Díaz de Santiago A, Rodríguez A, Calzado Isbert S, Aguilera García M, Morano Amado LE, Vinuesa García D, Bernal Morell E, Martínez Álvarez RM, Cabello-Clotet N, Fernández A, Montero Hernández MDC, Díez Romero C, Calderón Hernaiz R, Pérez Martínez D, Gisbert Pérez L, Arenas García V, Escrich C, Fariñas Álvarez MC, Lucas Dato A, Losa García JE, Pernas Pardavila H, Gainzarain JC, Estébanez M, Barragán Gallo P, Clavero Olmos M, Egido Murciano MV, Benéitez OLF, Pedrero-Tomé R, Cabello-Úbeda A, Martín-Carbonero L, RELATIVITY studygroup.   +38 more
europepmc   +1 more source

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. [PDF]

Clin Infect Dis
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF.   +15 more
europepmc   +1 more source

Correction to: Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. [PDF]

Open Forum Infect Dis
europepmc   +1 more source

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial. [PDF]

Lancet HIV
Lowenthal ED, Chapman J, Baltrusaitis K, Kovic G, Merchant S, Branch K, Tsosie C, Vaca MZ, Heckman B, Van Solingen-Ristea RM, Harrington CM, Yin DE, Townley E, Whitton M, Agwu AL, Smith C, Paul ME, Violari A, Moodley E, Owor M, Chokephaibulkit K, Fry S, Jao J, Mitchell CD, Buisson S, Ace A, Kolobova I, Bolton-Moore C, Gaur AH, IMPAACT 2017 Collaborators, IMPAACT 2017 Team.   +30 more
europepmc   +1 more source

Flip-Flop Pharmacokinetics in Pregnancy and the Future of Obstetric Pharmacology. [PDF]

J Clin Pharmacol
Eke AC.
europepmc   +1 more source

Detailed in silico Evaluation of WNV Proteins: Dynamic and Thermodynamic Insights into Doravirine as a Potential Multitarget Agent. [PDF]

Drug Des Devel Ther
Curcio A, Torti C, Quiros-Roldan E, Alcaro S, Artese A, Sparrow group.   +5 more
europepmc   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source